PIN11 COST SAVINGS FROM REDUCED HIV INCIDENCE ESTIMATES

Estimating Cost Savings from Early Cancer Diagnosis

We estimate treatment cost-savings from early cancer diagnosis. For breast, lung, prostate and colorectal cancers and melanoma, which account for more than 50% of new incidences projected in 2017, we combine published cancer treatment cost estimates by stage with incidence rates by stage at diagnosis. We extrapolate to other cancer sites by using estimated national expenditures and incidence ra...

Graphic Warning Labels and the Cost Savings from Reduced Smoking among Pregnant Women

Introduction: The U.S. Food and Drug Administration (FDA) has estimated the economic impact of Graphic Warning Labels (GWLs). By omitting the impact on tobacco consumption by pregnant women, the FDA analysis underestimates the economic benefits that would occur from the proposed regulations. There is a strong link between the occurrence of low birth weight babies and smoking while pregnant. Low...

The lifetime medical cost savings from preventing HIV in the United States.

OBJECTIVE Enhanced HIV prevention interventions, such as preexposure prophylaxis for high-risk individuals, require substantial investments. We sought to estimate the medical cost saved by averting 1 HIV infection in the United States. METHODS We estimated lifetime medical costs in persons with and without HIV to determine the cost saved by preventing 1 HIV infection. We used a computer simul...

Should Biomarker Estimates of HIV Incidence be Adjusted?

Reply to 'Should biomarker estimates of HIV incidence be adjusted?'.

OBJECTIVE To evaluate adjustment procedures that have been proposed to correct HIV incidence rates derived from cross-sectional surveys of biomarkers (e.g. BED capture enzyme immunoassay). These procedures were motivated by some reports that the biomarker BED approach overestimates incidence when compared to cohort studies. DESIGN Consideration of the Hargrove and McDougal adjustment procedur...